Magle Chemoswed Holding AB (MAGLE) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.26 times

Poor long term growth as Net Sales has grown by an annual rate of 15.39% over the last 5 years
Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.26 times
The company has been able to generate a Return on Capital Employed (avg) of 1.78% signifying low profitability per unit of total capital (equity and debt)
INTEREST(HY) At SEK 6.84 MM has Grown at 240.84%
OPERATING CASH FLOW(Y) Lowest at SEK -19.91 MM
ROCE(HY) Lowest at -5.85%

Risky -

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 430 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.51

Return on Equity

-3.81%

Price to Book

0.81

Revenue and Profits:

Net Sales:

52 Million

(Quarterly Results - Jun 2025)

Net Profit:

-28 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-15.28%

6 Months

-33.21%

1 Year

-45.54%

2 Years

-24.08%

3 Years

-31.45%

4 Years

-31.19%

5 Years

-44.24%

Magle Chemoswed Holding AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

15.39%

EBIT Growth (5y)

-280.56%

EBIT to Interest (avg)

-0.07

Debt to EBITDA (avg)

3.26

Net Debt to Equity (avg)

0.44

Sales to Capital Employed (avg)

0.60

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

1.78%

ROE (avg)

4.19%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.80

EV to EBIT

-35.00

EV to EBITDA

20.15

EV to Capital Employed

0.86

EV to Sales

2.41

PEG Ratio

Dividend Yield

ROCE (Latest)

-2.47%

ROE (Latest)

-3.81%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 13.91% vs 20.73% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -14,000.00% vs -95.74% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "52.40",
          "val2": "46.00",
          "chgp": "13.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-21.10",
          "val2": "4.10",
          "chgp": "-614.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.60",
          "val2": "1.40",
          "chgp": "157.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-27.80",
          "val2": "0.20",
          "chgp": "-14,000.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-562.20%",
          "val2": "2.70%",
          "chgp": "-56.49%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 38.50% vs 16.95% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -2.46% vs 34.07% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "236.00",
          "val2": "170.40",
          "chgp": "38.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "44.60",
          "val2": "23.10",
          "chgp": "93.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "11.30",
          "val2": "3.20",
          "chgp": "253.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "11.90",
          "val2": "12.20",
          "chgp": "-2.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "37.90%",
          "val2": "58.50%",
          "chgp": "-2.06%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

52.40

46.00

13.91%

Operating Profit (PBDIT) excl Other Income

-21.10

4.10

-614.63%

Interest

3.60

1.40

157.14%

Exceptional Items

0.00

Consolidate Net Profit

-27.80

0.20

-14,000.00%

Operating Profit Margin (Excl OI)

-562.20%

2.70%

-56.49%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 13.91% vs 20.73% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -14,000.00% vs -95.74% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

236.00

170.40

38.50%

Operating Profit (PBDIT) excl Other Income

44.60

23.10

93.07%

Interest

11.30

3.20

253.12%

Exceptional Items

0.00

Consolidate Net Profit

11.90

12.20

-2.46%

Operating Profit Margin (Excl OI)

37.90%

58.50%

-2.06%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 38.50% vs 16.95% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -2.46% vs 34.07% in Dec 2023

All Annual Results

Company CV

About Magle Chemoswed Holding AB

Magle Chemoswed Holding AB

Pharmaceuticals & Biotechnology

Magle Chemoswed Holding AB is a contract development manufacturing organization. The Company is located in Malmo, Sweden. It provides development and manufacturing services to healthcare companies as well as innovating and supplying new products based on the Company proprietary technology platform.

Company Coordinates

Company Details

Agneslundsvagen 27 , MALMO None : 212 15

Tel: 46 40 383300

Registrar Details